Prevention of Shivering During Therapeutic Temperature Modulation: The Columbia Anti-Shivering Protocol
Choi HA, Ko SB, Presciutti M, Fernandez L, Carpenter AM, Lesch C, Gilmore E, Malhotra R, Mayer SA, Lee K, Claassen J, Schmidt JM, Badjatia N. Prevention of Shivering During Therapeutic Temperature Modulation: The Columbia Anti-Shivering Protocol. Neurocritical Care 2011, 14: 389-394. PMID: 21210305, DOI: 10.1007/s12028-010-9474-7.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-2 Receptor AgonistsAdultAgedAnticonvulsantsConscious SedationCritical CareDexmedetomidineDose-Response Relationship, DrugFemaleFeverGlasgow Coma ScaleHeart ArrestHumansHypothermia, InducedIntensive Care UnitsIntracranial HypertensionMagnesium SulfateMaleMeperidineMiddle AgedMonitoring, PhysiologicNarcoticsNeuromuscular Nondepolarizing AgentsPropofolProspective StudiesShiveringVecuronium BromideConceptsPatient daysNeurological intensive care unitAnti-shivering agentsTherapeutic temperature modulationTotal patient daysPrevention of shiveringDoses of propofolIntensive care unitBaseline demographic informationNew clinical problemsInduced normothermiaMethodsAll patientsYounger patientsCare unitCumulative doseHigh riskClinical problemPatientsTemperature modulating devicesMore interventionsShiveringBaseline interventionDemographic informationFirst agentYoung men